DCC PLC
XMUN:DCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DCC PLC
XMUN:DCC
|
IE |
|
Dianthus Therapeutics Inc
F:87E
|
US |
|
T
|
Toyam Industries Ltd
BSE:538607
|
IN |
|
S
|
Semen Indonesia (Persero) Tbk PT
XMUN:SMS2
|
ID |
|
O
|
Olvi Oyj
F:OVI
|
FI |
Earnings Calls
Last Earnings Call
Revenue Decline: DCC reported revenue of GBP 7.4 billion for the first half, down from GBP 7.9 billion, driven by lower energy volumes and about 15% lower commodity pricing year-on-year.
Profit Down, Dividend Up: Operating profit fell 5.4% and adjusted EPS dropped 4.2%, but the interim dividend was increased by 5%, reflecting management's confidence.
Strategic Refocus: DCC completed the sale of its Healthcare and Info Tech businesses, shifting focus entirely to its energy segment, with major group simplification actions largely complete.
Large Capital Return: DCC is returning up to GBP 800 million to shareholders from asset sales, including a GBP 600 million tender offer to be completed by year-end.
Guidance Maintained: Despite a tough first half, DCC reiterated its guidance for good full-year operating profit growth and remains on track to double profits by 2030.